Welcome to the Medical Science Review

Medical Science Review (MSR) has developed as an independent title in 2014 as a continuation of highly successful Review Section of the Medical Science Monitor (since 1995). The aim of the Journal is to gather review articles across all medical disciplines, thereby integrating international medical knowledge. Medical Science Review has adopted the Open Access publishing model which enables free access... read more

Published: 2015-05-21

Pirfenidone and Nintedanib for Idiopathic Pulmonary Fibrosis: A New Drug Therapy

Priyanka Wani, Mohamed Teleb, Miraie Wardi, Hasan J. Salameh

(Department of Internal Medicine, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX, USA)

Med Sci Rev 2015; 2:41-48

DOI: 10.12659/MSRev.894308

ABSTRACT: Idiopathic pulmonary fibrosis (IPF) is a chronic debilitating disease with progressive decline in lung function. The incidence of IPF is higher in males, with median survival of 3–5 years after diagnosis. Recent clinical trials have shown success in effective treatment with pirfenidone and nintedanib. The purpose of this article was to review the literature and determine the safety and efficacy of pirfenidone and nintedanib in patients with IPF.
Pirfenidone is an oral drug with anti-fibrotic and anti-inflammatory properties. Three published phase III clinical studies have assessed pirfenidone in IPF (CAPACITY 004 and 006), assessed pirfenidone to confirm efficacy and safety in IPF (ASCEND), and a Japanese trials evaluated pirfenidone for mild-to-moderated IPF. The Japanese and ASCEND trials demonstrated that higher doses of pirfenidone decreased the rate of decline of FVC. The CAPACITY 004 and 006 showed that pirfenidone significantly reduced decline in forced vital capacity (FVC) compared with placebo. The efficacy data provided evidence of treatment benefit in patients with IPF.
Nintedanib is a tyrosine kinases inhibitor that inhibits the intracellular receptors of angiogenesis, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and fibroblast growth factor (FGF). There have been 2 published trials to improve pulmonary fibrosis with BIBF 1120 (TOMORROW), and high dose in Idiopathic Pulmonary Fibrosis patients (INPULSIS) 1 and 2 evaluating nintedanib for IPF. Both studies assessed nintedanib 150 mg twice daily in IPF patients compared to a placebo group, demonstrating that nintedanib is efficacious in reducin... read more

Keywords: Anti-Inflammatory Agents, idiopathic pulmonary fibrosis, Vital Capacity

Published: 2015-05-13

Metalloproteinases – their Role in Inflammatory Processes and Central Nervous System Diseases

Kinga Bobińska

Med Sci Rev 2015; 2:35-40

DOI: 10.12659/MSRev.894260

Published: 2015-04-25

ZMapp: A New Cocktail of Monoclonal Antibodies with Much Promise in Containing the Current Epidemic of Eb...

Ihsan Al-Bayati, Mohamed Teleb, Kevin Lowder, Hasan J. Salameh

Med Sci Rev 2015; 2:32-34

DOI: 10.12659/MSRev.894256